IP Verse

Combination Therapy For Prostate Cancer

Patent No. EP3609497 (titled "Combination Therapy For Prostate Cancer") was filed by Janssen Pharmaceutica on Apr 9, 2018. The application was issued on Oct 12, 2022.

Patent Summary

Antitumor drugs for men with metastatic castration-resistant prostate cancer (mCRPC). The drugs are niraparib, abiraterone acetate, and prednisone in a total amount that is therapeutically effective for the treatment of a prostate cancer in a human patient.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKJul 12, 2023RUSSELL
SANDOZJul 11, 2023ELKINGTON AND FIFE
TEVA PHARMACEUTICALSJul 6, 2023VON KAUFFMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3609497

JANSSEN PHARMACEUTICA
Application Number
EP18720895A
Filing Date
Apr 9, 2018
Status
Granted And Under Opposition
Sep 9, 2022
Publication Date
Oct 12, 2022
External Links
Slate, Register , Google Patents